Products for Research Use Only
RegisterLogin

Vociprotafib

CAT: 0804-HY-141523-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-141523-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Vociprotafib (RMC-4630) is an orally active, selective and potent phosphatase SHP2 inhibitor, which blocks activation of the RAS-RAF-MEK-ERK signaling pathway with antitumor activity. Vociprotafib accelerates the time to, and increases the magnitude of, tumor regressions in Osimertinib -sensitive EGFR-mutant tumors of mice[1][2][3].
CAS Number
2172652-48-9
Product Name Alternative
RMC-4630; SHP2-IN-7
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Phosphatase; SHP2
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vociprotafib.html
Purity
99.70
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
N[C@H]1C2(CO[C@H]1C)CCN(C3=NC(C)=C(SC4=CC=NC(N)=C4Cl)N=C3CO)CC2
Molecular Formula
C20H27ClN6O2S
Molecular Weight
450.99
Precautions
H302, H315, H319
References & Citations
[1]WO2018013597|[2]Ou S I, et al. A12 the SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: preliminary evaluation of a first-in-man phase 1 clinical trial[J]. Journal of Thoracic Oncology, 2020, 15 (2) : S15-S16.|[3]Smith J A, et al. SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway[J]. Cancer Research, 2020, 80 (16_Supplement) : 1943-1943.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Chemical Information

Vociprotafib

Vociprotafib is a small molecule drug. The usage of the INN stem '-protafib' in the name indicates that Vociprotafib is a human protein tyrosine phosphatase (HPTP) inhibitor. Vociprotafib is under investigation in clinical trial NCT05054725 (Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies). Vociprotafib has a monoisotopic molecular weight of 450.16 Da.

CAS Number2172652-48-9
PubChem CID134182831
IUPAC Name[6-[(2-amino-3-chloro-4-pyridinyl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl]methanol
Molecular FormulaC20H27ClN6O2S
Molecular Weight451.0
XLogP1.2
Topological Polar Surface Area149
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count9
Rotatable Bond Count4
Heavy Atom Count30
Formal Charge0
Complexity583
SMILES
C[C@H]1[C@H](C2(CCN(CC2)C3=NC(=C(N=C3CO)SC4=C(C(=NC=C4)N)Cl)C)CO1)N
InChI
InChI=1S/C20H27ClN6O2S/c1-11-19(30-14-3-6-24-17(23)15(14)21)26-13(9-28)18(25-11)27-7-4-20(5-8-27)10-29-12(2)16(20)22/h3,6,12,16,28H,4-5,7-10,22H2,1-2H3,(H2,23,24)/t12-,16+/m0/s1
InChIKey
HISJAYUQVHMWTA-BLLLJJGKSA-N
Chemical Structure
2D Structure
2D structure of Vociprotafib
CAS: 2172652-48-9
CID: 134182831
Formula: C20H27ClN6O2S
MW: 451.0
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight451.0
XLogP31.2
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count9
Rotatable Bond Count4
Exact Mass450.1604730
Monoisotopic Mass450.1604730
Topological Polar Surface Area149 Ų
Heavy Atom Count30
Formal Charge0
Complexity583
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Popular Products